Mainz Biomed Announces Stock Split
Mainz Biomed N.V. - Ordinary Shares (MYNZ)
Company Research
Source: GlobeNewswire
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024. The reverse stock split is expected to become effective on December 3, 2024 (the "Effective Date"), and the Company’s ordinary shares are expected to begin trading on the split-adjusted basis on the Nasdaq under the Company's existing trading symbol "MYNZ" at market open on December 3, 2024, upon Nasdaq's approval. The new CUSIP number for the Company's ordinary shares following the reverse stock split will be N5436L119. The reverse stock split is intended to increase the market price pe
Show less
Read more
Impact Snapshot
Event Time:
MYNZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYNZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYNZ alerts
High impacting Mainz Biomed N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MYNZ
News
- Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening TestGlobeNewswire
- Mainz Biomed Announces Closing of $8.0 Million Follow-On OfferingGlobeNewswire
- Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq RulesGlobeNewswire
- Mainz Biomed (NASDAQ: MYNZ) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.MarketBeat
- Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global MarketsGlobeNewswire
MYNZ
Analyst Actions
- 11/25/24 - HC Wainwright
MYNZ
Sec Filings
- 12/16/24 - Form 6-K
- 12/16/24 - Form 424B3
- 12/13/24 - Form 6-K
- MYNZ's page on the SEC website